significantClinical trial
Phase II trial of ixazomib-dexamethasone shows oral-only regimen feasibility
POEMS Syndrome →Summary
Dispenzieri et al. (2022) reported the first prospective trial of oral proteasome inhibitor ixazomib plus dexamethasone in POEMS, achieving hematologic response in 71% and neurologic improvement in 78% of patients. This all-oral regimen offers a convenient alternative for transplant-ineligible patients unable to attend frequent infusion visits.
More from POEMS Syndrome
significantTreatment update
Daratumumab emerging as treatment option for relapsed POEMS
significantDiagnostic advance
VEGF validated as reliable response biomarker across treatment modalities
incrementalTreatment update
Improved transplant outcomes in the modern era
incrementalTreatment update
Lenalidomide plus dexamethasone long-term data confirm durable responses
ID: poems-syndrome-update-9Type: clinical_trialImpact: significant